Variant NM_000492.4:c.254G>A
Name | NM_000492.4:c.254G>A |
Protein name | NP_000483.3:p.(Gly85Glu) |
Genomic name (hg19) | chr7:g.117149177G>A UCSC |
#Exon/intron | exon 3 |
Legacy Name | G85E |
Class | disease-causing |
Subclass | CF-causing |
WT sequence | TTTTTCTGGAGATTTATGTTCTATG G AATCTTTTTATATTTAGGGGTAAGG |
Mutant sequence | TTTTTCTGGAGATTTATGTTCTATG A AATCTTTTTATATTTAGGGGTAAGG |
dbSNP rs75961395 |
Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
IVA | no | no | no | no |
TEZ-IVA | no | no | no | no |
ELX-TEZ-IVA | yes | no | yes | no |
clinical and functional data are provided by Vertex
1 individuals carrying this variant are reported in CFTR-NGS catalogue |
TOTAL NUMBER OF PATIENTS | 39 |
---|---|
CF | 30 |
CFTR-RD | 7
|
Pending (NBS) | 2 |
Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
Phenotype | Patient ID | Variant status | Additional variants |
---|---|---|---|
CF | 17 | heterozygote | CF-causing - Trans |
CF | 2220 | heterozygote | CF-causing- Undef |
CF | 2475 | heterozygote | CF-causing- Undef |
CF | 2799 | heterozygote | CF-causing- Undef |
CF | 2985 | heterozygote | CF-causing - Trans |
CF | 2986 | heterozygote | CF-causing - Trans |
CF | 4967 | heterozygote | CF-causing - Trans |
CF | 3649 | heterozygote | CF-causing- Undef |
CF | 3826 | heterozygote | CF-causing- Undef |
CF | 3960 | heterozygote | CF-causing- Undef |
CF | 4332 | heterozygote | varying clinical consequence - Trans |
CF | 4339 | heterozygote | varying clinical consequence - Trans |
CF | 4340 | heterozygote | varying clinical consequence - Trans |
CF | 4341 | heterozygote | CF-causing - Trans VUS1 - Trans |
CF | 4379 | heterozygote | CF-causing - Trans |
CF | 2154 | heterozygote | CF-causing- Undef |
CF | 1959 | heterozygote | CF-causing- Undef |
CF | 1927 | heterozygote | CF-causing- Undef |
CF | 267 | heterozygote | CF-causing- Undef |
CF | 307 | heterozygote | CF-causing - Trans |
CF | 310 | heterozygote | CF-causing - Trans |
CF | 5515 | heterozygote | VUS3 - Trans |
CF | 5516 | heterozygote | VUS3 - Trans |
CF | 1036 | heterozygote | CF-causing - Trans |
CF | 5389 | heterozygote | CF-causing- Undef |
CF | 1779 | heterozygote | CF-causing- Undef |
CF | 4867 | heterozygote | CFTR-RD-causing- Undef |
CF | 1206 | heterozygote | CF-causing - Trans |
CF | 1172 | heterozygote | CF-causing - Trans |
CF | 172 | homozygote | c.254G>A - p.(Gly85Glu) - Trans |
Pending (NBS) | 4693 | heterozygote | CFTR-RD-causing - Trans |
Pending (NBS) | 6011 | heterozygote | varying clinical consequence- Undef |
CRS-NP | 4384 | heterozygote | varying clinical consequence - Trans |
CRS-NP | 295 | heterozygote | CFTR-RD-causing - Trans |
Pancreatitis | 648 | heterozygote | CFTR-RD-causing - Trans |
CBAVD | 2425 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 3734 | heterozygote | CF-causing- Undef |
CBAVD | 1759 | heterozygote | CFTR-RD-causing- Undef |
Bronchiectasis | 5112 | heterozygote | varying clinical consequence- Undef |
Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
CFTR variants are clustered into five groups: |
|